Drug Information

Drug General Information
Drug ID
D0Z9GM
Former ID
DIB004379
Drug Name
LY-2940094
Indication Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] Phase 2 [524117]
Company
Eli Lilly & Co
Target and Pathway
Target(s) Nociceptin receptor Target Info Modulator [551571], [551633]
KEGG Pathway Neuroactive ligand-receptor interaction
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 524117ClinicalTrials.gov (NCT01724112) Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD). U.S. National Institutes of Health.
Ref 551571UK Journal of Pharmaceutical and Biosciences Vol. 3(1), 12-17, 2015.
Ref 551633Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.